These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 36949303)
21. Update on the use of MR for assessment and diagnosis of psychiatric diseases. Agarwal N; Port JD; Bazzocchi M; Renshaw PF Radiology; 2010 Apr; 255(1):23-41. PubMed ID: 20308442 [TBL] [Abstract][Full Text] [Related]
28. The emerging tale of microglia in psychiatric disorders. Rahimian R; Wakid M; O'Leary LA; Mechawar N Neurosci Biobehav Rev; 2021 Dec; 131():1-29. PubMed ID: 34536460 [TBL] [Abstract][Full Text] [Related]
29. Suicide and Microglia: Recent Findings and Future Perspectives Based on Human Studies. Suzuki H; Ohgidani M; Kuwano N; Chrétien F; Lorin de la Grandmaison G; Onaya M; Tominaga I; Setoyama D; Kang D; Mimura M; Kanba S; Kato TA Front Cell Neurosci; 2019; 13():31. PubMed ID: 30814929 [TBL] [Abstract][Full Text] [Related]
33. Glial Cell Abnormalities in Major Psychiatric Diseases: A Systematic Review of Postmortem Brain Studies. Liu SH; Du Y; Chen L; Cheng Y Mol Neurobiol; 2022 Mar; 59(3):1665-1692. PubMed ID: 35013935 [TBL] [Abstract][Full Text] [Related]
34. Principles of inflammasome priming and inhibition: Implications for psychiatric disorders. Herman FJ; Pasinetti GM Brain Behav Immun; 2018 Oct; 73():66-84. PubMed ID: 29902514 [TBL] [Abstract][Full Text] [Related]
35. Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population. Martins SS; Gorelick DA Drug Alcohol Depend; 2011 Dec; 119(1-2):28-36. PubMed ID: 21641123 [TBL] [Abstract][Full Text] [Related]
36. Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers. Koutsouleris N; Meisenzahl EM; Borgwardt S; Riecher-Rössler A; Frodl T; Kambeitz J; Köhler Y; Falkai P; Möller HJ; Reiser M; Davatzikos C Brain; 2015 Jul; 138(Pt 7):2059-73. PubMed ID: 25935725 [TBL] [Abstract][Full Text] [Related]
37. Microglia-neuron crosstalk: Signaling mechanism and control of synaptic transmission. Marinelli S; Basilico B; Marrone MC; Ragozzino D Semin Cell Dev Biol; 2019 Oct; 94():138-151. PubMed ID: 31112798 [TBL] [Abstract][Full Text] [Related]
38. The cannabinoid system and microglia in health and disease. Duffy SS; Hayes JP; Fiore NT; Moalem-Taylor G Neuropharmacology; 2021 Jun; 190():108555. PubMed ID: 33845074 [TBL] [Abstract][Full Text] [Related]
39. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy. Levite M J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016 [TBL] [Abstract][Full Text] [Related]
40. CD200-, CX3CL1-, and TREM2-mediated neuron-microglia interactions and their involvements in Alzheimer's disease. Zhang L; Xu J; Gao J; Wu Y; Yin M; Zhao W Rev Neurosci; 2018 Nov; 29(8):837-848. PubMed ID: 29729150 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]